This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sun, Z. Articles by Privette, R. M. Search for Related Content PubMed Articles by Sun, Z. Articles by Privette, R. M. Social Bookmarking                         What's this?

ß-Casomorphin Induces Fos-Like Immunoreactivity in Discrete Brain Regions Relevant to Schizophrenia and Autism

University of Florida, USA

J. Robert Cade

University of Florida, USA

Melvin J. Fregly

University of Florida, USA

R. Malcolm Privette

University of Florida, USA

The induction of Fos-like immunoreactivity (FLI) was used to determine the brain localization affected by b-casomorphin-7 (b-CM7). Peripheral administration of human b-CM7 at different doses (5, 10 and 30 mg/kg, IV for 1 hour) to rats induced moderate to strong FLI in discrete brain regions including the nucleus accumbens, caudate putamen, ventral tegmental and median raphe nucleus, and orbitofrontal, prefrontal, parietal, temporal, occipital and entorhinal cortex. All of the above areas have been shown to be altered either functionally or anatomically in patients with schizophrenia, and most have been shown to be functionally abnormal in autism. Some of these brain areas are originators or components of dopaminergic, serotoninergic and GABA-ergic pathways, suggesting that b-CM7 can affect the function of all of these systems. The role of some other affected areas in emotional and motivated behavior, social adaptation, hallucinations and delusions suggests that b-CM7, which was found in high concentration in the CSF, blood and urine of patients with either schizophrenia or autism, may be relevant to schizophrenia and autism. Induction of FLI in the above brain areas by a moderate dose (10 mg/kg) of b-CM7 was attenuated significantly, or blocked, by pretreatment with naloxone (2 mg/kg, IP). It is concluded that human b-CM7 can cross the blood-brain barrier, activate opioid receptors and affect brain regions similar to those affected by schizophrenia and autism.

Key Words: autism • brain • casomorphin • Fos • gene • naloxone • schizophrenia

Autism, Vol. 3, No. 1, 67-83 (1999)
DOI: 10.1177/1362361399003001006


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. H. Elder The Gluten-Free, Casein-Free Diet in Autism: An Overview With Clinical Implications Nutr Clin Pract, December 1, 2008; 23(6): 583 - 588. [Abstract] [Full Text] [PDF]

				J. F. White Intestinal Pathophysiology in Autism Experimental Biology and Medicine, June 1, 2003; 228(6): 639 - 649. [Abstract] [Full Text] [PDF]

				Z. Sun and J. R. Cade A Peptide Found in Schizophrenia and Autism Causes Behavioral Changes in Rats Autism, March 1, 1999; 3(1): 85 - 95. [Abstract] [PDF]